Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders

References

• Centers for Disease Control. HIV among women; 2016. Available from: http://www.cdc.gov/hiv/group/gender/women/. Accessed September 22, 2016.
   Google Scholar
• Collins R, Ellickson P, Orlando M, Klein D. Isolating the nexus of substance use, violence and sexual risk for HIV infection among young adults in the United States. AIDS Behav. 2005;9(1):73–87. doi:10.1007/s10461-005-1683-2
   PubMed Web of Science ®Google Scholar
• Stoner S, Norris J, George W, et al. Women’s condom use assertiveness and sexual risk-taking: effects of alcohol intoxication and adult victimization. Addict Behav. 2008;33(9):1167–1176. doi:10.1016/j.addbeh.2008.04.017
   PubMed Web of Science ®Google Scholar
• Seth P, Wingood GM, DiClemente RJ, Robinson LS. Alcohol use as a marker for risky sexual behaviors and biologically confirmed sexually transmitted infections among young adult African-American women. Womens Health Issues. 2011;21(2):130–135. doi:10.1016/j.whi.2010.10.005
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment, and Care for Key Populations. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: Updated to 2020. Washington, D.C.: Health Resources and Services Administration; 2015.
   Google Scholar
• HIV.gov. Ending the HIV epidemic: a plan for America; 2019. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Accessed September 23, 2019.
   Google Scholar
• Chen N, Meyer J, Springer S. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infect Dis Rep. 2011;3(1):e6. doi:10.4081/idr.2011.2362
   PubMedGoogle Scholar
• Blankenship KM, Reinhard E, Sherman SG, El-Bassel N. Structural interventions for HIV prevention among women who use drugs: a global perspective. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S140–S145. doi:10.1097/QAI.0000000000000638
   Web of Science ®Google Scholar
• Office of Research on Women’s Health. Moving into the future with new dimensions and strategies: a vision for 2020 for women’s health research. 2010.
   Google Scholar
• Wizeman T, Pardue M. Exploring the biological contributions to human health: does sex matter? Washington, DC. 2001.
   Google Scholar
• Seidman D, Weber S. Integrating preexposure prophylaxis for human immunodeficiency virus prevention into women’s health care in the United States. Obstet Gynecol. 2016;128(1):37–43. doi:10.1097/AOG.0000000000001455
   PubMed Web of Science ®Google Scholar
• Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80(4):460–462. doi:10.2105/AJPH.80.4.460
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174. doi:10.1126/science.1193748
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi:10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434. doi:10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Hanscom B, Janes HE, Guarino PD, et al. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73(5):606–608. doi:10.1097/QAI.0000000000001160
   PubMed Web of Science ®Google Scholar
• Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep. 2011;1:185. doi:10.1038/srep00185
   Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2013;381(9883):2083–2090. doi:10.1016/S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• Page K, Tsui J, Maher L, et al. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S169–S175. doi:10.1097/QAI.0000000000000641
   Web of Science ®Google Scholar
• Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr. 2013;63(Suppl 1):S95–S101. doi:10.1097/QAI.0b013e3182920126
   PubMed Web of Science ®Google Scholar
• Garnett GP, Hallett TB, Takaruza A, et al. Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study. Lancet HIV. 2016;3(7):e297–e306. doi:10.1016/S2352-3018(16)30039-X
   Web of Science ®Google Scholar
• Elopre L, Kudroff K, Westfall AO, Overton ET, Mugavero MJ. The right people, right places, and right practices: disparities in PrEP access among African American men, women and MSM in the deep south. J Acquir Immune Defic Syndr. 2016;74(1):56.
   Web of Science ®Google Scholar
• Garfinkel DB, Alexander KA, McDonald-Mosley R, Willie TC, Decker MR. Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients. AIDS Care. 2016;29:1–8.
   Web of Science ®Google Scholar
• Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–110. doi:10.1089/apc.2014.0142
   PubMed Web of Science ®Google Scholar
• Jayakumaran JS, Aaron E, Gracely EJ, Schriver E, Szep Z, Clark JL. Knowledge, attitudes, and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS One. 2016;11(2):e0145670. doi:10.1371/journal.pone.0145670
   PubMed Web of Science ®Google Scholar
• Koechlin FM, Fonner VA, Dalglish SL, et al. Values and preferences on the use of oral Pre-exposure Prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2016;21:1–11.
   Web of Science ®Google Scholar
• Shrestha R, Karki P, Altice FL, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107–116. doi:10.1016/j.drugalcdep.2016.12.023
   PubMed Web of Science ®Google Scholar
• Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition–United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
   PubMed Web of Science ®Google Scholar
• Iversen J, Page K, Madden A, Maher L. HIV, HCV, and health-related harms among women who inject drugs: implications for prevention and treatment. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S176–S181. doi:10.1097/QAI.0000000000000659
   PubMed Web of Science ®Google Scholar
• Mera R, McCallister S, Palmer B, Mayer G, Mangnuson D, Rawlings K. Abstract TUAX0105LB: FTC/TDF (Truvada) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2013–2015. 21st International AIDS Conference; 2016; Durban, South Africa.
   Google Scholar
• Sewell WC, Solleveld P, Seidman D, Dehlendorf C, Marcus JL, Krakower DS. Patient-led decision-making for HIV preexposure prophylaxis. Curr HIV/AIDS Rep. 2021;18(1):48–56. doi:10.1007/s11904-020-00535-w
   Web of Science ®Google Scholar
• Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;(1):Cd001431. doi:10.1002/14651858.CD001431.pub4
   Web of Science ®Google Scholar
• Powell V, Mayer K, Maloney K, Wong J, Wilson I, Krakower D. Impact of a clinical decision aid for prescribing HIV preexposure prophylaxis to men who have sex with men on primary care provider knowledge and intentions. International Conference on HIV Treatment and Prevention Adherence; 2018; Miami, FL.
   Google Scholar
• Krakower D, Powell V, Maloney K, Wong J, Wilson I, Mayer K. Impact of a personalized clinical decision aid on informed decision-making about HIV preexposure prophylaxis among men who have sex with men. International Conference on HIV Treatment and Prevention Adherence; 2018; Miami, FL.
   Google Scholar
• Madden LM, Farnum SO, Eggert KF, et al. An investigation of an open-access model for scaling up methadone maintenance treatment. Addiction. 2018;113(8):1450–1458. doi:10.1111/add.14198
   PubMed Web of Science ®Google Scholar
• Qin Y, Price C, Rutledge R, Puglisi L, Madden LM, Meyer JP. Women’s decision-making about PrEP for HIV prevention in drug treatment contexts. J Int Assoc Provid AIDS Care. 2020;19:2325958219900091. doi:10.1177/2325958219900091
   Google Scholar
• Elwyn G, O’Connor A, Stacey D, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333(7565):417. doi:10.1136/bmj.38926.629329.AE
   PubMed Web of Science ®Google Scholar
• Gray MJ, Litz BT, Hsu JL, Lombardo TW. Psychometric properties of the life events checklist. Assessment. 2004;11(4):330–341. doi:10.1177/1073191104269954
   PubMed Web of Science ®Google Scholar
• Eisen SV, Normand SL, Belanger AJ, Spiro A, Esch D. The revised Behavior and Symptom Identification Scale (BASIS-R): reliability and validity. Med Care. 2004;42(12):1230–1241. doi:10.1097/00005650-200412000-00010
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Jerusalemn M. Generalized self-efficacy scale. In: Weinman J, Wright S, Johnston M, editors. Measures in Health Psychology: A User’s Portfolio. Causal and Control Beliefs. Windsor, UK: NFER-NELSON; 1995:35–37.
   Google Scholar
• Rosen C, Henson B, Finney J, Moos R. Consistency of self-administered and interview-based addiction severity index composite scores. Addiction. 2000;95(3):419–425. doi:10.1046/j.1360-0443.2000.95341912.x
   PubMed Web of Science ®Google Scholar
• Reinert D, Allen J. The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res. 2002;26(2):272–279. doi:10.1111/j.1530-0277.2002.tb02534.x
   PubMed Web of Science ®Google Scholar
• O’Connor EA, Perdue LA, Senger CA, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320(18):1910–1928. doi:10.1001/jama.2018.12086
   PubMed Web of Science ®Google Scholar
• McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199–213.
   PubMed Web of Science ®Google Scholar
• Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44–52. doi:10.1097/01.qai.0000192000.15777.5c
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection – 2014: a clinical practice guideline. Available from: http://stacks.cdc.gov/view/cdc/231092014. Accessed September 23, 2019.
   Google Scholar
• Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States- 2017 update, a clinical practice guideline; 2018. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed August 12, 2021.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2016 National Survey on Drug Use and Health. Rockville, Maryland: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS. 2017;31(5):731–734. doi:10.1097/QAD.0000000000001385
   PubMed Web of Science ®Google Scholar
• Williams N, Kogan R. Factors associated with evidence-based decision-making among patients and providers. J Comp Eff Res. 2019;8(9):709–719. doi:10.2217/cer-2018-0152
   PubMed Web of Science ®Google Scholar
• Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care. 2018;30:1–8.
   Web of Science ®Google Scholar
• PrEP Eligibility and HIV Risk Perception for Women across the Criminal Justice Continuum in Connecticut.  12th Academic and Health Policy on Conference on Correctional Health.  Las Vegas, Nevada.  March 2019.
   Google Scholar
• Huang Y-LA, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity - United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
   PubMed Web of Science ®Google Scholar
• Mera Giler R, Magnuson D, Trevor H, Bush S, Rawlings K, McCallister S. WEPEC0919: changes in truvada (TVD) for HIV pre-exposure prophylaxis (PreP) utilization in the United States: 2012–2016. International AIDS Society Conference; 2017; Paris, France.
   Google Scholar
• Knittel AK, Lambdin BH, Comfort ML, Kral AH, Lorvick J. Sexual risk and criminal justice involvement among women who use drugs. AIDS Behav. 2019;23(12):3366–3374. doi:10.1007/s10461-019-02447-2
   PubMed Web of Science ®Google Scholar
• Knittel AK, Shook-Sa BE, Rudolph J, et al. Incarceration and number of sexual partners after incarceration among vulnerable US women, 2007–2017. Am J Public Health. 2020;110(S1):S100–S108. doi:10.2105/AJPH.2019.305410
   PubMed Web of Science ®Google Scholar
• Sareen J, Pagura J, Grant B. Is intimate partner violence associated with HIV infection among women in the United States? Gen Hosp Psychiatry. 2009;31(3):274–278. doi:10.1016/j.genhosppsych.2009.02.004
   PubMed Web of Science ®Google Scholar
• Calabrese SK, Willie TC, Galvao RW, et al. Current US guidelines for prescribing HIV Pre-Exposure Prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. J Acquir Immune Defic Syndr. 2019;81:395–405. doi:10.1097/QAI.0000000000002042
   PubMed Web of Science ®Google Scholar
• Bradley ELP, Hoover KW. Improving HIV preexposure prophylaxis implementation for women: summary of key findings from a discussion series with women’s HIV prevention experts. Womens Health Issues. 2019;29(1):3–7. doi:10.1016/j.whi.2018.08.004
   PubMed Web of Science ®Google Scholar
• Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal considerations on alcohol and HIV/AIDS–a systematic review. Alcohol Alcohol. 2010;45(2):159–166. doi:10.1093/alcalc/agp091
   PubMed Web of Science ®Google Scholar
• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–193. doi:10.1016/j.drugalcdep.2010.06.014
   PubMed Web of Science ®Google Scholar
• Wagman JA, Wynn A, Matsuzaki M, et al. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS. 2020;34(15):2285–2294. doi:10.1097/QAD.0000000000002716
   Web of Science ®Google Scholar
• Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158–170. doi:10.1016/j.drugalcdep.2017.01.026
   PubMed Web of Science ®Google Scholar
• Springer SA, Di Paola A, Azar M, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr. 2018;78:43.
   PubMed Web of Science ®Google Scholar
• Tross S, Campbell AN, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr. 2008;48(5):581–589. doi:10.1097/QAI.0b013e31817efb6e
   PubMed Web of Science ®Google Scholar
• Shrestha R, Weikum D, Copenhaver M, Altice FL. The influence of neurocognitive impairment, depression, and alcohol use disorders on health-related quality of life among incarcerated, HIV-infected, opioid dependent Malaysian men: a moderated mediation analysis. AIDS Behav. 2017;21(4):1070–1081. doi:10.1007/s10461-016-1526-3
   PubMed Web of Science ®Google Scholar
• Arias F, Arnsten JH, Cunningham CO, et al. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults. Addict Behav. 2016;60:137–143. doi:10.1016/j.addbeh.2016.03.018
   PubMed Web of Science ®Google Scholar
• Shrestha R, Huedo-Medina TB, Altice FL, Krishnan A, Copenhaver M. Examining the acceptability of mHealth technology in HIV prevention among high-risk drug users in treatment. AIDS Behav. 2017;21(11):3100–3110. doi:10.1007/s10461-016-1637-x
   Web of Science ®Google Scholar
• El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. Curr Opin HIV AIDS. 2012;7(4):326–331. doi:10.1097/COH.0b013e3283536ab2
   Web of Science ®Google Scholar
• Dore G, Mills K, Murray R, Teesson M, Farrugia P. Post-traumatic stress disorder, depression and suicidality in inpatients with substance use disorders. Drug Alcohol Rev. 2012;31(3):294–302. doi:10.1111/j.1465-3362.2011.00314.x
   PubMed Web of Science ®Google Scholar
• Mills KL, Lynskey M, Teesson M, Ross J, Darke S. Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): prevalence and correlates. Drug Alcohol Depend. 2005;77(3):243–249. doi:10.1016/j.drugalcdep.2004.08.016
   PubMed Web of Science ®Google Scholar
• Willie TC, Keene DE, Kershaw TS, Stockman JK. “You never know what could happen”: women’s perspectives of pre-exposure prophylaxis in the context of recent intimate partner violence. Womens Health Issues. 2020;30(1):41–48. doi:10.1016/j.whi.2019.08.001
   PubMed Web of Science ®Google Scholar
• Singer M. AIDS and the health crisis of the U.S. urban poor; the perspective of critical medical anthropology. Soc Sci Med. 1994;39(7):931–948. doi:10.1016/0277-9536(94)90205-4
   PubMed Web of Science ®Google Scholar
• Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health (Larchmt). 2011;20(7):991–1006. doi:10.1089/jwh.2010.2328
   PubMed Web of Science ®Google Scholar
• Mathers BM, Cooper DA. Integrating HIV prevention into practice. JAMA. 2014;312(4):349–350. doi:10.1001/jama.2014.8606
   Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration Center; 2015.
   Google Scholar
• Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S155–S161. doi:10.1097/QAI.0000000000000637
   PubMed Web of Science ®Google Scholar
• Prendergast ML, Urada D, Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol. 2001;69(3):389–405. doi:10.1037/0022-006X.69.3.389
   PubMed Web of Science ®Google Scholar
• Crits-Christoph P, Gallop R, Sadicario JS, et al. Predictors and moderators of outcomes of HIV/STD sex risk reduction interventions in substance abuse treatment programs: a pooled analysis of two randomized controlled trials. Subst Abuse Treat Prev Policy. 2014;9:3. doi:10.1186/1747-597X-9-3
   PubMed Web of Science ®Google Scholar
• El-Bassel N, Strathdee SA. Women who use or inject drugs: an action agenda for women-specific, multilevel, and combination HIV prevention and research. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S182–S190. doi:10.1097/QAI.0000000000000628
   PubMed Web of Science ®Google Scholar